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ABSTRACT 
Objective: Vaspin is a novel adipocytokine with potential insulin-sensitizing properties. 
Insulin resistance (IR) plays a role in the development and progression of 
atherosclerosis. However, the relationship between serum vaspin levels and 
atherosclerosis remains unknown. Therefore, we investigated whether vaspin was 
correlated with carotid intima-media thickness (c-IMT). 
Methods: Data for fasting vaspin levels of 201 subjects (78 men and 123 women aged 
over 40 years) were obtained from a general population in Japan. We obtained 
anthropometric parameters and blood chemistries, and calculated homeostasis model 
assessment-IR (HOMA-IR) index. C-IMT was measured by B-mode ultrasonography. 
The mean values of each parameter by tertiles of vaspin were compared with analysis of 
variance, and the associations of vaspin with IR and c-IMT were evaluated by multiple 
stepwise regression analysis. 
Results: Univariate analysis revealed that vaspin levels were positively correlated with 
BMI, insulin, HOMA-IR index, estimated glomerular filtration rate (eGFR), c-IMT and 
hypertensive medication. Multiple stepwise regression analysis revealed that HOMA-IR 
index, c-IMT and eGFR were significantly and independently associated with vaspin. 
We performed multivariate analyses with c-IMT as the dependent variable. Age, 
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hypertensive medication and vaspin were significant for c-IMT. Moreover, a mediation 
analysis demonstrated that vaspin was significantly related to c-IMT, independently of 
IR. 
Conclusions: The present study not only confirmed the previous finding of the positive 
association of vaspin with IR but also demonstrated that serum vaspin level was 
positively associated with c-IMT, independently of IR in a general population. Our 
results may suggest a role of vaspin in atherosclerosis in humans. 
 
Keywords: Vaspin, Insulin resistance, Carotid atherosclerosis, Epidemiology 
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1. Introduction 
Vaspin was first identified from visceral adipose tissues of Otsuka Long-Evans 
Tokushima Fatty (OLETF) rats, an animal model of type 2 diabetes mellitus with 
obesity and insulin resistance (IR) [1]. It is one of the visceral adipose tissue-derived 
adipocytokines, which belongs to the family of serine protease inhibitor (serpin) [2]. 
Adipose tissue expression of vaspin was significantly increased when obesity peaked in 
OLETF rats and administration of vaspin to obese mice improved glucose tolerance and 
insulin sensitivity [1]. Thereafter, many in vitro and in vivo animal studies 
demonstrated insulin-sensitizing capacity of vaspin [3-5].  
In humans, vaspin appears to have an insulin sensitizing properties [6] as well. 
Some clinical studies regarding to regulation of human vaspin have shown that serum 
levels are positively associated with IR [7,8] and the values are decreased following 
weight reduction and short-term intensive lifestyle modification [9], and restrictive 
bariatric surgery and laparoscopic Roux-en-Y gastric bypass (RYGB) surgery [10,11]. 
Thus, observations of animal and human studies suggest that vaspin could be a novel 
adipocytokine with an insulin-sensitizing property. 
Recently, it has been considered that vaspin may possess anti-atherosclerotic 
properties. However, there have been a few data available for the association of vaspin 
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with atherosclerosis [12,13]. Accordingly, we investigated whether serum vaspin levels 
were correlated with intima-media thickness of the carotid artery, a marker of 
subclinical atherosclerosis in a general population. 
 
2. Methods 
2.1. Study population 
A total of 226 subjects (86 men and 140 women) aged over 40 years received a 
population-based health examination in a fishing community in southwestern Japan, 
Uku town, in 2008. This town is an isolated island in Sasebo city, located in Nagasaki 
prefecture, and the total population is about 3,700. Of these, we excluded 25 subjects 
whose vaspin data were missing or who rejected the blood tests. Consequently, 201 
subjects (78 men and 123 women) were enrolled in this study.  
 
2.2. Data collection 
Height and weight were measured, and body mass index (BMI) was calculated 
as weight (kilograms) divided by the square of height (square meters) as an index of the 
presence or absence of obesity. Waist circumference was measured at the level of the 
umbilicus in a standing position. Blood pressure (BP) was measured twice with the 
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subjects in the sitting (first) and supine (second) position. Vigorous physical activity and 
smoking were avoided for at least 30 minutes before BP measurements. The second BP 
with the fifth phase diastolic pressure was used for analysis. Blood was drawn from the 
antecubital vein for determinations of lipids profiles (high-density lipoprotein 
cholesterol [HDL-cholesterol], low-density lipoprotein cholesterol [LDL-cholesterol] 
and triglycerides), creatinine, uric acid (UA), fasting plasma glucose (FPG), insulin, 
glycated hemoglobin A1c [HbA1c (NGSP)] and serum vaspin levels in a morning after 
12-hour fasting. Fasting blood samples were centrifuged within 1 hour after the 
collection. Estimated glomerular filtration rate (eGFR) was calculated using the 
Modification of Diet in Renal Disease (MDRD) study equation modified with a 
Japanese coefficient [14]. Serum vaspin levels were measured with an enzyme-linked 
immunosorbent assay (ELISA) system [1]. Intra- and inter-assay coefficients of 
variation of vaspin in a commercially available laboratory (AdipoGen Inc. Incheon, 
Korea) were 2.8% and 6.1%, respectively.  
HOMA-IR index was calculated from FPG and insulin levels [FPG (mg/dl) × 
insulin (μU/ml)/405] as a marker of IR. Subjects with type 2 diabetes mellitus were 
defined as those with FPG≥126 mg/dl or HbA1c≥6.5%, or those taking oral 
hypoglycemic agents and receiving insulin injection. C-IMT of the common carotid 
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artery was determined by using duplex ultrasonography (Sonosite“TITAN”, ALOKA) 
with a 10-MHz transducer in the supine position. Longitudinal B-mode images at the 
diastolic phase of the cardiac cycle were recorded by a single trained technician who 
was blinded to the subjects’ background. We measured the only far wall of c-IMT. The 
images were magnified and measured on the screen, and printed with a high-resolution 
line recorder (LSR-100A, Toshiba). We measured c-IMT according to the originally 
described method published in Circulation. Briefly, the c-IMT defined by Pignoli et al. 
[15,16] was measured as the distance from the leading edge of the first echogenic line to 
the leading edge of the second echogenic line. The first line represented the 
lumen-intimal interface; the collagen-containing upper layer of the tunica adventitia 
formed the second line. At each longitudinal projection, the site of the greatest thickness, 
including plaque, was sought along the arterial walls nearest the skin and farthest from 
the skin from the common carotid artery to the internal carotid artery. Three 
determinations of c-IMT of one artery were conducted at the site of the greatest 
thickness and at 2 other points, 1 cm upstream and 1 cm downstream from this site. The 
averaged value among the 6 IMTs (3 from the left and 3 from the right) was used as the 
representative value for each individual. 
The mayor and the welfare section of Uku town approved this study. The 
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ethical committee of Kurume University also approved this study. All participants gave 
informed consent. 
 
2.3. Statistical analysis 
Because of skewed distributions, the natural logarithmic (ln) transformations 
were performed for triglycerides, insulin, HOMA-IR and vaspin. Log-transformed 
values were reconverted to antilogarithm forms in the tables. The medications for 
hypertension, dyslipidemia, and type 2 diabetes mellitus were coded as dummy 
variables. First, we performed multivariate analyses with vaspin as a dependent variable, 
and then with the c-IMT as a dependent variable. Finally, we performed a mediation 
analysis by creating a structural equation model to see whether vaspin was directly 
related to c-IMT. Statistical significance was defined as p<0.05. All statistical analyses 
were performed using the SAS system (Release 9.3, SAS Institute, Cary, NC). 
 
3. Results 
Characteristics of the subjects stratified by tertiles of vaspin are shown in Table 
1. BMI (p<0.05), insulin (p<0.05), HOMA-IR (p<0.01), c-IMT (p<0.05) and 
hypertensive medication (p<0.05) were positively associated with serum vaspin level, 
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whereas eGFR (p<0.05) was inversely associated. Characteristics of the subjects 
stratified by tertiles of c-IMT are shown in Table 2. Age (p<0.001), vaspin (p<0.05) and 
hypertensive medication (p<0.001) were positively associated with c-IMT, whereas 
eGFR (p<0.01) was inversely associated.  
Multiple stepwise regression analysis revealed that serum vaspin level was 
significantly and independently associated with eGFR (p<0.01; inversely), HOMA-IR 
(p<0.05) and c-IMT (p<0.05) (Table 3a). Multiple stepwise regression analysis also 
revealed that c-IMT was significantly and independently associated with age (p<0.001), 
hypertensive medication (p<0.01) and vaspin (p<0.05) (Table 3b).  
The result of the mediation analysis is presented in the Table 4 with path 
diagram in the Figure 1. We found that HOMA-IR was not related to c-IMT, and vaspin 
was directly related to c-IMT although vaspin was related to both c-IMT and 
HOMA-IR. 
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4. Discussion 
 In this cross-sectional cohort study in a general population, multiple stepwise 
regression analysis revealed that serum vaspin levels were significantly and 
independently associated with HOMA-IR index and c-IMT, markers of IR and carotid 
atherosclerosis, respectively. Moreover, a mediation analysis demonstrated that vaspin 
was directly related to c-IMT, independently of IR. 
 
Vaspin and Insulin Resistance 
Our results are consistent with previous studies showing a close association of serum 
vaspin level with IR [6,17,18] in humans. Previously, it was demonstrated that serum 
vaspin levels were associated with not only IR but also BMI in adults [6,17,18], 
children [19,20] and obese women with polycystic ovary syndrome [21,22]. However, 
there was no association of vaspin with BMI in our study. Because obesity and IR is 
closely related, no association of BMI with vaspin levels in our study may be puzzling. 
As apparent from Table 1, most enrolled subjects had normal BMI. Thus, absence of 
obesity in our population may explain this discrepant result from previous ones. 
Previous studies [22-24] demonstrated the influence on the regulation of vaspin by 
therapeutic agents such as statin, metformin and oral contraceptives. Thus, we should 
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not overlook effects of drugs on serum vaspin level. In our study, twenty subjects were 
prescribed statin, but the results were same after excluding subjects on statin. Moreover, 
the subjects on metformin or oral contraceptives were not included.  
Because the clinical nature of our study, we are not able to state whether the 
high vaspin levels in insulin resistant subjects are primary or secondary. Basic in vitro 
and animal data suggest the compensatory elevation of vaspin in insulin resistant 
subjects [5,7,25]. 
 
Vaspin and Atherosclerosis 
  In this study, we for the first time demonstrated a close association of serum 
vaspin with c-IMT. Careful literature search revealed information for serum vaspin with 
atherosclerosis is very scanty. In a clinical study of 37 women with type 2 diabetes [26], 
the presence of microvascular complications was associated with low vaspin levels. 
However, the report was for microvascular diseases but not for atherosclerosis. The 
association of serum vaspin with carotid stenosis was reported in patients with acute 
ischemic stroke [27] and patients undergoing carotid endarterectomy [28]. No 
association was found in either study [27,28]. One clinical study reported a positive 
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association of serum vaspin with coronary atherosclerosis in asymptomatic women with 
metabolic syndrome [29]. However, no studies have been performed for the 
investigation of c-IMT, a surrogate marker of subclinical atherosclerosis, in a general 
population. We, for the first time, demonstrated a positive association of serum vaspin 
level with atherosclerosis in a general population. Although in order to elucidate the 
role of vaspin in atherosclerosis, it may be desirable to investigate the relationship 
before atherosclerosis has fully developed, it is necessary to investigate the relationship 
in established atherosclerotic patients as well. 
  From our study, we are not able to say why serum vaspin levels are increased 
in subjects with carotid atherosclerosis. Previous animal and human studies suggest 
vaspin may have anti-atherosclerotic properties [12,13,30]. Thus, it is likely that vaspin 
levels may be compensatory elevated. Although it is the beyond the scope of our study, 
we like to consider the anti-atherosclerotic properties of vaspin as follows. In cultured 
human aortic endothelial cells, vaspin prevented free fatty acid-induced apoptosis of 
endothelial cells through a stimulatory effect on the insulin-signaling pathway [30]. 
Thus, it is possible that vaspin will exert its anti-atherosclerotic properties through the 
insulin-sensitizing capacity [2,5-7]. However, our results suggest rather the direct effect 
of vaspin on atherosclerosis because the association of vaspin with c-IMT was 
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independent of HOMA-IR. We carried out an additional analysis to investigate direct 
and indirect relationship of vaspin with c-IMT by using a structural equation model with 
observed variables. The mediation analysis demonstrated that vaspin was directly 
related to c-IMT, independently of IR (Table 4 with path diagram in the Figure 1). The 
change in c-IMT for 10% increase in vaspin was 0.022.  
The following basic studies may support our hypothesis [12,13,30]. A recent 
report demonstrated that vaspin increased nitric oxide bioavailability through the 
reduction of ADMA, an endogenous inhibitor of nitric oxide synthesis, in vascular 
endothelial cells [12]. It was shown that vaspin inhibited apoptosis as a ligand for the 
cell-surface GRP78 (78-kDa glucose-regulated protein)/voltage-dependent anion 
channel complex) in endothelial cells and inhibited apoptosis of endothelial cells [13]. 
Moreover, Phalitakul S, et al. [31] demonstrated that vaspin inhibited platelet-derived 
growth factor-BB-induced migration of vascular smooth muscle cells (SMCs) and 
protected the development of atherosclerosis in rats. 
Multiple stepwise regression analysis revealed that serum vaspin levels were 
significantly and inversely associated with eGFR (Table 3a) suggesting renal function 
may affect serum vaspin levels. In fact, the molecular size of vaspin is too big 
(approximately 50-kDa) to be secreted from the kidney [2,32]. Although we have no 
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good explanation, the small number of enrolled subjects may be responsible. Our 
finding may be similar to that of Seeger et al. [33] who also demonstrated that 
circulating vaspin was inversely associated with eGFR in univariate analyses in control 
subjects. However, this association was lost after adjusting for age and gender. Thus, 
further studies are needed to elucidate the association of serum vaspin and renal 
function. 
 
5. Limitations 
The present study has several limitations. First, this study was cross-sectional 
and comparatively a small number of cases. Thus, nothing conclusive for the 
association of vaspin with atherosclerosis is stated. Prospective studies with a large 
number are needed to investigate the role of vaspin in the development of 
atherosclerosis. Second, our population was relatively healthy, and most of them had 
BMI, c-IMT and HOMA-IR index within normal limits. Thus, it is necessary to 
investigate serum vaspin levels in heterogeneous populations with wide ranges of 
atherosclerosis. 
 
6. Conclusions 
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 In conclusion, our data indicated that human circulating vaspin was positively 
and independently associated with HOMA-IR index and c-IMT in a general population. 
Vaspin may have a role in atherosclerosis.  
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Figure Legend 
 
Figure 1: Path diagram by the result of mediation analysis is presented. 
 
Endogenous 
variable Exogenous variable Estimate SE z p‐value 95%CI 
c-IMT intercept 0.359 0.048 7.55 0.000 (0.266, 0.452)
Vaspin* 0.022 0.010 2.19 0.029 (0.002, 0.042)
HOMA-IR* -0.005 0.011 -0.48 0.628 (-0.027, 0.016)
Age 0.005 0.001 7.11 0.000 (0.004, 0.007)
Hypertensive 
medication 0.044 0.015 2.99 0.003 (0.010, 0.073)
Vaspin* intercept 0.413 0.226 1.83 0.068 (-0.015, -0.003)
eGFR -0.009 0.003 -3.04 0.002 (-0.030, 0.855)
HOMA-IR* intercept 0.043 0.048 0.89 0.374 (-0.052, 0.137)
Vaspin* 0.174 0.065 2.67 0.008 (0.046, 0.303)
c‐IMT
eGFR Vaspin*
HOMA‐IR*
age
Hypertensive 
medication
p=0.002
‐0.009
0.174
p=0.008
‐0.005
p=0.628
0.022
p=0.029
0.005
P<0.0001
0.044
p=0.003
*:These variables are shown in the original scale after analysis using log (natural)‐transformed values.
Table 4. Results of the mediation analysis
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Table 1. Characteristics of study subjects stratified by tertiles of serum vaspin levels 
 
Variable Tertiles of serum vaspin levels p-value
 T1 (n=67) T2 (n=67) T3 (n=67)  
Vaspin* (ng/ml) 0.36 (0.17-0.58) 0.76 (0.59-1.00) 1.68 (1.01-1.74) <0.001
Age (years) 64.5 (10.1) 66.6 (9.8) 66.1 (9.8) 0.454 
Male gender: n (%males) 24 (35.8) 30 (44.8) 24 (35.8) 0.306 
BMI (kg/m2) 23.4 (2.8) 23.6 (3.2) 24.6 (2.8) 0.038 
Waist (cm) 84.8 (9.1) 84.6 (9.4) 86.7 (9.1) 0.384 
Waist-Hip ratio 0.91 (0.06) 0.91 (0.05) 0.92 (0.05) 0.476 
Systolic BP (mmHg) 138.5 (17.7) 136.4 (19.9) 138.5 (17.0) 0.753 
Diastolic BP (mmHg) 79.3 (9.6) 80.8 (11.5) 81.3 (10.2) 0.533 
LDL-cholesterol (mg/dl) 119.4 (31.7) 117.1 (29.0) 122.1 (27.5) 0.617 
HDL-cholesterol (mg/dl) 61.4 (15.3) 58.5 (12.1) 57.0 (14.4) 0.184 
Triglycerides* (mg/dl) 83.0 (37-286) 82.0 (32-218) 93.3 (34-393) 0.252 
FPG (mg/dl) 93.3 (17.6) 99.0 (27.6) 97.4 (12.6) 0.254 
Insulin* (µU/ml) 3.7 (0.5-16.4) 4.1 (0.9-11.6) 5.0 (0.9-18.2) 0.011 
HOMA-IR*  0.85 (0.12-3.93) 0.98 (0.23-5.54) 1.19 (0.20-4.58) 0.009 
HbA1c (%, NGSP) 5.0 (0.7) 5.0 (0.6) 5.0 (0.4) 0.894 
eGFR (ml/min/1.73m2) 75.4 (15.8) 72.0 (16.2) 67.9 (14.4) 0.023 
Uric Acid (mg/dl) 5.1 (1.4) 5.3 (1.4) 5.5 (1.4) 0.228 
c-IMT (mm) 0.69 (0.12) 0.72 (0.11) 0.74 (0.10) 0.043 
Alcohol intake: n (%yes) 17 (32.7) 16 (30.8) 19 (36.5) 0.836 
Current smoking: n (%yes) 8 (38.1) 5 (23.8) 8 (38.1) 0.623 
Medications: n (%yes)     
 Hypertension 22 (32.8) 28 (41.8) 37 (55.2) 0.035 
 Type 2 diabetes mellitus 1 (1.5) 4 (6.0) 3 (4.5) 0.227 
 Dyslipidemia 9 (13.4) 10 (14.9) 5 (7.5) 0.391 
Data are means (SD), geometric mean, range, or percent. 
*:These variables are shown in the original scale after analysis using log (natural)-transformed 
values. 
  eGFR was calculated by the Modification of Diet in Renal Disease (MDRD) study equation 
[eGFR=194×Creatinin-1.094×Age-0.287 (×0.739 if female)]. 
  Abbreviations: BMI, body mass index; BP, blood pressure; FPG, fasting plasma glucose; 
HOMA-IR, homeostasis model assessment-insulin resistance; eGFR, estimated glomerular 
filtration rate; c-IMT, carotid intima-media thickness 
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Table 2. Characteristics of study subjects stratified by tertiles of c-IMT levels 
 
Variable Tertiles of c-IMT levels p-value
 T1 (n=67) T2 (n=67) T3 (n=67)  
c-IMT (mm) 0.59 (0.07) 0.71 (0.04) 0.85 (0.06) <0.001
Age (years) 59.6 (9.3) 67.4 (8.6) 70.5 (8.4) <0.001
Male gender: n (%males) 25 (37.3) 22 (32.8) 31 (46.3) 0.074 
BMI (kg/m2) 23.6 (2.9) 24.1 (2.9) 23.7 (3.1) 0.585 
Waist (cm) 83.6 (9.4) 86.4 (9.3) 86.1 (8.7) 0.167 
Waist-Hip ratio 0.89 (0.05) 0.91 (0.05) 0.92 (0.05) 0.054 
Systolic BP (mmHg) 134.4 (17.8) 138.0 (17.2) 141.3 (19.2) 0.098 
Diastolic BP (mmHg) 79.9 (10.9) 80.2 (10.9) 81.2 (9.4) 0.764 
LDL-cholesterol (mg/dl) 120.8 (32.9) 119.3 (29.4) 118.5 (25.5) 0.899 
HDL-cholesterol (mg/dl) 61.4 (16.8) 56.9 (12.6) 58.7 (11.8) 0.173 
Triglycerides* (mg/dl) 84.8 (32-371) 90.0 (37-318) 84.8 (34-393) 0.295 
FPG (mg/dl) 94.0 (15.6) 98.1 (27.5) 97.6 (14.2) 0.439 
Insulin* (µU/ml) 4.1 (1.0-14.7) 4.7 (0.5-18.2) 3.9 (0.9-13.3) 0.139 
HOMA-IR*  0.95 (0.20-4.32) 1.11 (0.12-5.54) 0.92 (0.20-4.09) 0.187 
HbA1c (%, NGSP) 4.9 (0.6) 5.1 (0.7) 5.0 (0.4) 0.155 
eGFR (ml/min/1.73m2) 76.3 (14.8) 71.2 (15.7) 67.5 (15.7) 0.005 
Uric Acid (mg/dl) 5.3 (1.5) 5.2 (1.3) 5.4 (1.4) 0.446 
Vaspin* (ng/ml) 0.65 (0.17-4.23) 0.80 (0.17-3.17) 0.90 (0.26-5.67) 0.024 
Alcohol intake: n (%yes) 20 (29.8) 15 (22.4) 17 (25.4) 0.508 
Current smoking: n (%yes) 12 (17.9) 4 (6.0) 5 (7.5) 0.052 
Medications: n (%yes)     
 Hypertension 17 (25.4) 34 (50.7) 36 (53.7) <0.001
 Type 2 diabetes mellitus 2 (3.0) 2 (3.0) 4 (6.0) 0.495 
 Dyslipidemia 4 (5.9) 12 (17.9) 8 (11.9) 0.121 
Data are means (SD), geometric mean, range, or percent. 
*:These variables are shown in the original scale after analysis using log (natural)-transformed 
values. 
  eGFR was calculated by the Modification of Diet in Renal Disease (MDRD) study equation 
[eGFR=194×Creatinin-1.094×Age-0.287 (×0.739 if female)]. 
  Abbreviations: BMI, body mass index; BP, blood pressure; FPG, fasting plasma glucose; 
HOMA-IR, homeostasis model assessment-insulin resistance; eGFR, estimated glomerular 
filtration rate; c-IMT, carotid intima-media thickness
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Table 3a. Multiple stepwise regression analysis for the correlates of vaspin* 
 
Parameters ßeta SE p-value 
eGFR (ml/min/1.73m2) -0.009 0.003 0.003 
HOMA-IR* 0.182 0.075 0.016 
c-IMT (mm) 0.828 0.418 0.048 
                                                         R2=0.091 
Abbreviations: eGFR, estimated glomerular filtration rate; 
HOMA-IR, homeostasis model assessment-insulin resistance; 
c-IMT, carotid intima-media thickness 
SE, Standard error 
*:This variable is shown in the original scale after analysis using log (natural)- 
 transformed value. 
 
 
Table 3b. Multiple stepwise regression analysis for the correlates of c-IMT 
 
Parameters ßeta SE p-value 
Age (years) 0.006 0.001 <0.001 
Hypertensive medication 0.047 0.015 0.002 
Vaspin* (ng/ml) 0.022 0.010 0.035 
                                                            R2=0.295 
Abbreviations: c-IMT, carotid intima-media thickness; SE, Standard error 
*:This variable is shown in the original scale after analysis using log (natural)-transformed 
 value. 
